Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for IPA within the last 6 months
See all filings within the past 6 months

Company News

Jun 17, 2021 08:28 ET
Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced additional results from its in vivo hamster challenge efficacy study of TATX-03a PolyTope™ Therapy, a four monoclonal antibody cocktail being developed for the potential prevention and treatment of SARS-CoV-2, demonstrating reduced bronchitis and tracheitis inflammation severity. The Company concurrently announced optimization results of TATX-03 cocktail components designed to improve clinical suitability of their PolyTope therapy.
Read full article
Jun 15, 2021 08:28 ET
Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event
IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro characterizations investigating TATX-21, a novel potential first-in-class antibody for Atherosclerosis Cardiovascular Disease (ACVD), will be presented in partnering meetings at the 2021 BIO International Convention, June 14-18, 2021.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 31, 202137,648-8,365
May 15, 202146,013913
Apr 30, 202145,10015,308
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Immunoprecise Antibodies Ltd, formerly Tanqueray Exploration Ltd, is a Canada-based supplier of custom hybridoma development services. The Company's geographical segments include United States of America and Canada. It offers products, such as antibodies and hybridoma licensing. It offers various services, such as ImmunoProtect, Monoclonal Development, Polyclonal Development, Antibody Protection, Peptide Production and Cryopreservation Services. Its antibody products include IPA006A, IPA006B and IPA006F, which it offers to the research and industrial community. Its hybridoma licensing products include Anti-Human P38a (MAPKinase) Monoclonal Antibody Hybridoma Cell Line and Anti-Acetylated Lysine Monoclonal Antibody Hybridoma Cell Line. It offers cryopreservation storage service for the secure storage of users' valuable biological materials, including hybridoma clones, plasmid constructs and cell lines. It also offers both peptide synthesis and protein carrier conjugation services.

See business summary



Search (past week) for $IPA.CA IPA.V